Age-dependent prognostic effects of EGFR/p53 alterations in glioblastoma: Study on a prospective cohort of 140 uniformly treated adult patients

Journal of Clinical Pathology

Volumn 63, Issue 8, 2010, Pages 687-691

  Srividya, M R ^a   Thota, Balaram ^a   Arivazhagan, A ^a   Thennarasu, K ^a   Balasubramaniam, A ^a   Chandramouli, B A ^a   Hegde, A S ^b   Santosh, Vani ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b SRI SATHYA SAI INSTITUTE OF HIGHER MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOREACTIVITY; MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN INTERACTION; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BRAIN NEOPLASMS; EPIDEMIOLOGIC METHODS; GENES, P53; GLIOBLASTOMA; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 77955739038     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.074898     Document Type: Article

References (73)

1. Kleihues P, Louis DN, Wiestler OD, et al. WHO grading of tumors of central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classification of tumors of the central nervous system. Lyon, France: IARC Press, 2007:10-11.
2. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25. (Pubitemid 34212595)
3. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710. (Pubitemid 350070717)
4. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008;9:29-38.
5. Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009;18:1061-83.
6. Eric CB, Kathleen RL, Peter F, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002;8:180-7.
7. Stark AM, Witzel P, Strege RJ, et al. p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme. J Neurol Neurosurg Psychiatry 2003;74:779-83. (Pubitemid 36628293)
8. Hurtt MR, Moossy J, Donovan-Peluso M, et al. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 1992;51:84-90.
9. Schiebe M, Ohneseit P, Hoffmann W, et al. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol 2000;49:197-203. (Pubitemid 32106781)
10. Sehgal A. Molecular changes during the genesis of human gliomas. Semin Surg Oncol 1998;14:3-12. (Pubitemid 128774930)
11. von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia 1995;15:328-38.
12. Barker F, Simmons M, Chang S, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:410-18. (Pubitemid 32888171)
13. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56. (Pubitemid 32816199)
14. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 2003;10:212-17.
15. Rasheed BK, Wiltshire RN, Bigner SH, et al. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 1999;11:162-7.
16. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999;1:44-51.
17. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26. (Pubitemid 23046372)
18. Wemmert S, Ketter R, Rahnenführer J, et al. Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 2005;7:883-93.
19. Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age <50 years. Cancer 2005;104:825-32. (Pubitemid 41113684)
20. Umesh S, Tandon A, Santosh V, et al. Clinical and immunohistochemical prognostic factors in adult glioblastoma patients. Clin Neuropathol 2009;28:362-72.
21. Donato V, Papaleo A, Castrichino A, et al. Prognostic implication of clinical and pathologic features with glioblastoma multiforme treated with concomitant radiation plus Temozolomide. Tumori 2007;93:248-56. (Pubitemid 47080010)
22. Etienne MC, Formento JL, Lebrun-Frenay C, et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 1998;4:2383-90. (Pubitemid 28477903)
23. Korkolopoulou P, Christodoulou P, Kouzelis K, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997;75:1269-78. (Pubitemid 27179815)
24. Jaros E, Perry RH, Adam L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labeling in brain tumors. Br J Cancer 1992;66:373-85.
25. Diedrich V, Lucius J, Baron E, et al. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 1995;242:683-8.
26. Korshunov A, Sycheva R, Golanov A. Molecular stratification of diagnostically challenging high-grade gliomas composed of small cells: the utility of fluorescence in situ hybridisation. Clin Cancer Res 2004;10:7820-6. (Pubitemid 39587519)
27. Zhu A, Shaeffer J, Leslie S, et al. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 1996;34:809-15. (Pubitemid 26089218)
28. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-8. (Pubitemid 34266783)
29. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 2000;12:107-12.
30. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70. (Pubitemid 37322983)
31. Torp SH, Helseth E, Dalen A, et al. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir (Wien) 1992;117:182-6.
32. Birner P, Piribauer M, Fischer I, et al. Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep 2002;9:703-7.
33. Kapoor GS, Christie A, O'Rourke DM. EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53. Cancer Biol Ther 2007;6:571-9. (Pubitemid 47328332)
34. Saito T, Hama S, Kajiwara Y, et al. Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas. Anticancer Res 2006;26:1351-7.
35. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex association between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001;61:1122-8.
36. Layfield LJ, Willmore C, Tripp S, et al. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol 2006;14:91-6.
37. Rainov NG, Dobberstein KU, Bahn H, et al. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 1997;35:13-28. (Pubitemid 27361842)
38. Waha A, Baumann A, Wolf HK, et al. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor alpha pathway in human astrocytic gliomas. J Neurosurg 1996;55:634-41. (Pubitemid 26315197)
39. Ruano Y, Ribalta T, de Lope AR, et al. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol 2009;131:257-63.
40. Newcomb EW, Cohen H, Lee SR, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or bcl-2 genes. Brain Pathol 1998;8:655-67.
41. Stark AM, Hugo HH, Witzel P, et al. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir 2003;64:30-6. (Pubitemid 36176306)
42. Batchelor TT, Betensky RA, Espositi JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004;10:228-33.
43. Liu L, Backlund LM, Nilsson BR, et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 2005;83:917-26. (Pubitemid 41598692)
44. Cunningham JM, Kimmel DW, Scheithauer BW, et al. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 1997;86:121-30.
45. Olson JJ, Barnett D, Yang J, et al. Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 1998;4:215-22. (Pubitemid 28062899)
46. Houillier C, Lejeune J, Benouaich-Amiel A. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006;106:2218-23. (Pubitemid 43673244)
47. Rich JN, Christopher H, Beatrix J, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 2005;65:4051-8.
48. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462-6. (Pubitemid 40315227)
49. Korshunov A, Golanov A, Sycheva R, et al. Prognostic value of tumour associated antigens immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol 1999;52:574-80. (Pubitemid 29371901)
50. Soini Y, Niemela A, Kamel D, et al. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS 1994;102:786-92.
51. Tada M, Matsumoto R, Iggo RD, et al. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 1998;58:1793-7. (Pubitemid 28217448)
52. Baxendine-Jones J, Campbell I, Ellison D. p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 1997;16:332-6. (Pubitemid 27483785)
53. Chozick BS, Pezzullo JC, Epstein MH, et al. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 1994;35:831-7.
54. Kyritsis AP, Bondy ML, Hess KR, et al. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1995;1:1617-22.
55. Rasheed BK, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994;54:1324-30.
56. Martin V, Mazzucchelli L, Frattini M. An overview of the epidermal growth factor receptor fluorescence in situ hybridization challenge in tumour pathology. J Clin Pathol 2009;62:314-24.
57. Kleihues P, Burger PC, Aldape KD, et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classification of tumors of the central nervous system. Lyon, France: IARC Press 2007:33-47.
58. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992;89:4309-13.
59. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-9. (Pubitemid 39330996)
60. Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 1987;84:6899-903.
61. Ekstrand AJ, James CD, Cavenee WK, et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-72.
62. Biernat W, Huang H, Yokoo H, et al. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004;14:131-6. (Pubitemid 38656384)
63. Tohma Y, Gratas C, Biernat W, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998;57:684-9. (Pubitemid 28335057)
64. Yoon KS, Lee MC, Kang SS, et al. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma. J Korean Med Sci 2001;16:481-8.
65. Louis DN. A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7:755-64.
66. Watanabe K, Tachibana O, Sato K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-24. (Pubitemid 26246377)
67. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 1983;52:997-1007.
68. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 2000;5:213-31.
69. Prados MD, Gutin PH, Phillips TL, et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 1992;23:3-8.
70. van Tol KM, de Vries EG, Dullaart RP, et al. Differentiated thyroid carcinoma in the elderly. Crit Rev Oncol Hematol 2001;38:79-91.
71. Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001;84:1377-83. (Pubitemid 32522107)
72. Garvin AM, Eppenberger U, Müller H, et al. BRCA1 mutations found in archived early onset breast tumours. Eur J Cancer 1997;33:683-6. (Pubitemid 27223757)
73. Bogdani M, Teugels E, De Grève J, et al. Loss of nuclear BRCA1 localization in breast carcinoma is age dependent. Virchows Arc 2002;440:274-9. (Pubitemid 34230731)